Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 9Neuroendocrine Tumors 8Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 5Stomach Neoplasms 4Sarcoma 4Cholangiocarcinoma 4Ovarian Neoplasms 3Osteosarcoma 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroectodermal Tumors, Primitive 1NSCLC 1Lymphoma 1Locally Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 4envafolimab 3Nivolumab 3Injections 2trifluridine tipiracil drug combination 1tebentafusp 1surufatinib 1sintilimab 1linifanib 1fludarabine 1cobimetinib 1TAK-981 1Ipilimumab 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Combined Modality Therapy 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced or Metastatic Solid Tumors × surufatinib × Clear all
NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡